Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel-Carboplatin + Bevacizumab in Metastatic TNBC
NCT00691379Phase 2Completed
- Sponsor
- Hellenic Oncology Research Group
- Start
- Apr 2008
- Primary completion
- Mar 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in triple-negative breast cancer (TNBC), sponsored by Hellenic Oncology Research Group. Started Apr 2008; status: completed.
02
Drugs
bevacizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT00691379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00691379.